Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 40 (3) , 198-203
Abstract
Objective. To evaluate the process of hormonal recovery after cessation of luteinizing hormone-releasing hormone (LHRH) agonist treatment in patients who had received long-term LHRH agonist therapy for prostate cancer. Material and methods. Men who had successfully undergone androgen deprivation therapy with only monthly LHRH agonist therapy for > 30 months were enrolled and the administration of LHRH agonist was discontinued. Serum total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prostate-specific antigen (PSA) were measured before the cessation of LHRH agonist therapy and every 4 weeks thereafter, and the administration of LHRH agonist remained suspended until the total testosterone level recovered to > 50 ng/dl. Results. Ten patients were enrolled in the study. The median (range) castration period and the levels of serum LH, FSH, total testosterone and PSA at cessation of therapy were 39 (30–56) months,Conclusions. There was considerable variation in the hypothalamus–pituitary–testicular hormone profiles during recovery from long-term medical castration. These findings are noteworthy when interruption of androgen deprivation therapy is applied with the intention of delaying the progression of hormone-refractory cancer or improving the patient's quality of life.Keywords
This publication has 10 references indexed in Scilit:
- Quality-of-Life Outcomes After Primary Androgen Deprivation Therapy: Results From the Prostate Cancer Outcomes StudyJournal of Clinical Oncology, 2001
- A PROSPECTIVE ANALYSIS OF TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, 2000
- A Pilot Study of Intermittent Androgen Ablation in Advanced Prostate Cancer in Japanese MenJapanese Journal of Clinical Oncology, 2000
- Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessmentUrology, 1999
- Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancerUrology, 1999
- Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour modelThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- Intermittent androgen suppression in the treatment of prostate cancer: A preliminary reportUrology, 1995
- The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic TestsJournal of Urology, 1994
- Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaPThe Prostate, 1993
- Testicular Histology after Treatment with LH‐RH Analogue for Carcinoma of the ProstateBritish Journal of Urology, 1990